Q: I'd like to know from Ryan Modesto or Peter Hodson his opinion on Vitalhub tsxv (VHI). They are penetrating the continuum of care business in mental health sector in Canada. What do you think of the fundamentals, margins, upside, downside and would you be an investor in the actual share price (0.16$) ? The company is at 20M market cap.
You can view 3 more answers this month. Sign up for a free trial for unlimited access.
Investment Q&A
Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.
Q: Im holding ERF.TO and paid an average share price of $18.00. I have 1800 shares and just wondering if this is a good holding for the next year. Is there a better energy company I should be invested in over the next year? Or maybe I should divest in my energy holding. Thanks.
Q: In reviewing ZWC distribution tax information for 2017, $.664 of the $1.12 distribution was deemed ROC with the remainder being eligible dividend. How is this possible? The ETF holds dividend paying companies. There is no operating business carried out that would have non cash items like depreciation that would constitute ROC. Gains realized on call writing would be capital gains. Where is this ROC coming from and is it cause for concern?
Q: Following up on my earlier question about QST. It reported what appeared to be good earnings with a good outlook but the stock is down today. Am I missing something? What is your take on things?
Q: I need to replace Enercare in my portfolio and was thinking of BBU.un. How do you rate BBU vs Enercare in terms of safety and growth? I realize I'd be sacrificing dividends for more growth here but the environment is not being kind to dividend stocks just now, and I can switch over if and when that changes.
Q: Any reason for the up move today?
-
Gilead Sciences Inc. (GILD)
-
AbbVie Inc. (ABBV)
-
Johnson & Johnson (JNJ)
-
Medtronic plc. (MDT)
-
Pfizer Inc. (PFE)
Q: Recently, 5i has supported members' suggestions to switch out of JNJ into something else given the legal difficulties that JNJ faces. I generally like to hold indefinitely; given this anticipated time frame, and my preference for safety and a good/growing dividend, do you think I should switch as well? Do you view the alternatives I've listed as less or more risky than JNJ overall? Are there non-pharmaceutical alternatives in the US healthcare space that would provide an equally secure and growing dividend that you would recommend? Thank you.
Q: Frustrated and selling it. Please advise replacement ( does not have to be in the same sector). Which stocks from the balanced portfolio look more attractive.
Thanks
Thanks
Q: Hi,
Thanks for the past tips to get into Savaria, I’m up 70% on it right now. They seem to have a hard time breaking through $17. Do they have anything solid in the works that you think will push it higher with support or do you think the best part of this ride is over? I haven’t held it long and don’t need the cash for anything, but would like to see continued solid returns. I know the returns here aren’t typical, but do you see somewhere else to better send the money or is it a hold for a while still?
Thanks
Thanks for the past tips to get into Savaria, I’m up 70% on it right now. They seem to have a hard time breaking through $17. Do they have anything solid in the works that you think will push it higher with support or do you think the best part of this ride is over? I haven’t held it long and don’t need the cash for anything, but would like to see continued solid returns. I know the returns here aren’t typical, but do you see somewhere else to better send the money or is it a hold for a while still?
Thanks
Q: Each of these had big falls in stock price, and each for different reasons. Which would you prefer for a quick bounce back and why?
Regards,
Robert
Regards,
Robert
Q: Can you please comment on the Earnings for $NFI and how the Market might react.
Thanks Valter
Thanks Valter
Q: Sangoma released preliminary numbers for fiscal 2018 which tops guidance. Based on management's comments on the current EBITDA quarterly run rate, the the current stock price seems deeply undervalued based on EV/EBITDA with net cash on hand metric, revenue multiple and M&A history. Do you agree?
Q: What is your take on the NFI Q2 results, and its forward looking information, just released today? Much appreciated.
Q: May I have your thoughts on a short term play on this stock after Musk’s announcement today? Thanks,
Jason
Jason
Q: Can you please comment on the Earnings for $GSY and how the Market might react.
Thanks Valter
Thanks Valter
Q: Hi, any comments on the secondary offering for $180 mln from primary shareholders and employees ? Thanks
Q: What is your view on Evolve Active CDN Pref Share ETF for an income investor?
Q: Good morning team,
Which Canadian stock to own in a portfolio rebalance from sale of Nutrien-?Would you please advise-Considering EMP.A or SJ or your choice?
Which Canadian stock to own in a portfolio rebalance from sale of Nutrien-?Would you please advise-Considering EMP.A or SJ or your choice?
Q: Would like your thoughts on CWX 2nd quarter report thanks.
Q: Greetings 5i,
At current price, would you add to PXT at this time or would you wait until after the quarterly report and maybe some comments from management on the conference call? Would be putting into my TFSA account. Don't have any E&Ps currently.
At current price, would you add to PXT at this time or would you wait until after the quarterly report and maybe some comments from management on the conference call? Would be putting into my TFSA account. Don't have any E&Ps currently.